In this article, we will take a look at some of the best growth stocks under $100 to buy now.

Even if asked by a layman where they would want to invest, the answer would be straight: growth stocks. A growth stock comes from companies that have expanding revenues, disruptive ideas, and outperform potential.

Over the years, Warren Buffett has shifted from being a value investor to a quality investor. He now realizes that higher long-term returns from high-quality companies can be generated even at higher valuations than value stocks. Additionally, Buffett’s long-term investment horizon has played a significant role in his successful investing tenure. As he says,

“Our favorite holding period is forever.”

Thus, this analysis is based on stocks that have prices lower than $100 but have high long-term potential. These companies, from biopharmaceutical to fashion, have one thing in common: a strategy for the long haul. Despite short-term fluctuations, high-growth stocks possess a clear path to expansion, innovation, and market leadership.

Our Methodology

In our analysis, we have incorporated stocks under $100 that have high growth potential. Using the Finviz screener, the stocks are filtered according to their price targets and analysts’ ratings. The stocks have been ranked according to the price target upside potential, based on the Yahoo Finance estimates, from the lowest to the highest.

Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here).

10. Urban Outfitters, Inc. (NASDAQ:URBN)

Upside potential as of June 11, 2025: 2.77%

Mark Altschwager, an analyst at Baird, raised the price target for Urban Outfitters, Inc. (NASDAQ:URBN) to $90 from $75, while elevating the rating from “Neutral” to “Outperform”. This price appreciation of 20% underscores the company’s position for a turnaround.

The company recently reported strong first-quarter results, with a 74% increase in net income stemming from margin improvement. The investors are closely monitoring the giant’s subscription/rental business, Nuuly, which is anticipated to grow 43% to $540m this year.

To sum it up, Urban Outfitters, Inc. (NASDAQ:URBN) is a unique “growth at a reasonable price” stock that is witnessing strong comp sales growth in each of its brands, and with even more room to grow via both price hikes and traffic increases. As long as the company is able to capitalize on Nuuly, we can expect it to show sustained momentum.

Urban Outfitters, Inc. (NASDAQ:URBN) is a Pennsylvania-based fashion business that operates through three segments: Retail, Wholesale, and Subscription. Incepted in 1970, the company serves its customers directly through websites and retail stores, as well as social media and external sources. While the broader market delivered nearly 100% return in five years, URBN has exhibited a return of 295%.

9. Verona Pharma plc (NASDAQ:VRNA)

Upside potential as of June 11, 2025: 7.8%

Analysts at Jefferies have raised the price target for Verona Pharma plc (NASDAQ:VRNA) to $110, up from $95, with an unchanged “Buy” rating. This was after the successful launch of the COPD treatment Ohtuvayre, which has witnessed strong sales growth.

During the first quarter, Ohtuvayre delivered $71 million in sales, reflecting an increase of nearly 90% from the previously reported 37 million in the last quarter. Verona Pharma plc (NASDAQ:VRNA) continues to capitalize on this growing demand, with peak sales projections between $3 billion and $5 billion. As the numbers suggest, this is anything but ordinary. The optimism surrounding the company’s profitability in the second quarter is just the cherry on top.

Some believe that Verona Pharma plc (NASDAQ:VRNA) is heading north to be the next big franchise. With its potential, Wall Street anticipates the giant to achieve $1 billion in sales by 2028, driven by its safety profile, global expansion, robust patent protection, and an underserved market of 398 million people with COPD.

Verona Pharma plc (NASDAQ:VRNA) is a London-based biopharmaceutical company that develops and markets therapies for treating patients suffering from respiratory diseases. Incorporated in 2005, the company is committed to improving the lives of many by offering innovative drugs.

8. CompoSecure, Inc. (NASDAQ:CMPO)

Upside potential as of June 11, 2025: 9.5%

CompoSecure, Inc. (NASDAQ:CMPO) recently disclosed that Tim Fitzsimmons, the Chief Financial Officer, will be retiring after his 13-year tenure. The retirement is set to take effect once a successor is in place, anticipated no later than the start of 2026.

To facilitate the smooth leadership transition, Fitzsimmons, who aided the company’s transition from a family-owned business into a publicly listed company, will serve as a consultant. With his role as a “proud shareholder”, we can expect little to change in the company’s growth avenues following his transition. It’s safe to say that this leadership transition showcases a new chapter for the giant’s growth prospects.

The company reiterates its previously issued full-year 2025 guidance, anticipating mid-single-digit growth in not only consolidated net sales but also pro forma adjusted EBITDA. TD Cowen reaffirms its “Buy” rating for the stock while maintaining a price target of $15. With its well-managed restructuring, we can expect CompoSecure, Inc. (NASDAQ:CMPO) to continue to leverage its involvement in the premium card market.

CompoSecure, Inc. (NASDAQ:CMPO) is a New Jersey-based company that designs and produces metal, composite, and proprietary financial transaction cards in the United States and worldwide. With a mission to be a trusted technology partner, the company operates through two segments: Payment Card and Arculus.

7. Insmed Incorporated (NASDAQ:INSM)

Upside potential as of June 11, 2025: 10.69%

The shares of Insmed Incorporated (NASDAQ:INSM) have witnessed a surge of about 32% in the course of five days following the success of Phase 2b of its once-daily pulmonary arterial hypertension (PAH) therapy, treprostinil palmitil inhalation powder (TPIP). The results were evaluated about 24 hours after the administration of the drug, showcasing a consistent benefit throughout the 24-hour dosing period.

Additionally, the company has revealed plans to initiate discussions with the U.S. Food and Drug Administration (FDA) to shape its Phase 3 trials roadmap. While this first Phase 3 trial will focus on pulmonary hypertension tied to interstitial lung disease by the year’s end, the second trial is designed for PAH patients in the coming year. By 2032, the global market for pulmonary arterial hypertension is set to climb to $12.2 billion.

The two anticipated phase 3 studies are enough to be excited about the company, yet there exists another breakthrough. Insmed Incorporated (NASDAQ:INSM) has finalized and submitted its New Drug Application (NDA) of brensocatib for treating patients with Non-cystic fibrosis bronchiectasis (NCFBE), with the date for review set for August 12, 2025. The company is indeed among the companies with high growth potential.

Insmed Incorporated (NASDAQ:INSM) is a New Jersey-based biopharmaceutical company that develops and markets therapies to treat patients with serious and rare diseases. With a global presence, the company is committed to transforming the lives of many.

6. Uber Technologies, Inc. (NYSE:UBER)

Upside potential as of June 11, 2025: 11.63%

Analysts at Stifel initiated the “Buy” rating for Uber Technologies, Inc. (NYSE:UBER), with a price target of $110, highlighting an upside of nearly 27%. The analysts believe the giant can meet or even exceed its 2024 targets, including mid-to-high-teens growth in gross bookings and a high EBITDA compound annual growth rate. The financials of the company reinforce a somewhat similar picture.

Just recently, Uber Technologies, Inc. (NYSE:UBER) inked the acquisition of Taiwan fleet dispatcher Crown Taxi in an attempt to enhance its presence in the Taiwanese market. While the deal is pending regulatory approval, if successful, it can offer Crown Taxi professional drivers a smoother working experience and increase passenger, in general.

For a company like Uber Technologies, Inc. (NYSE:UBER), there’s a lot to look forward to. The perfect blend of AI, ML, and cloud infrastructure positions the company as more than just a transportation provider. Given its record of losses, the company has managed to build a sustainable business model on the foundations of innovation and smart capital.

Uber Technologies, Inc. (NYSE:UBER) is a California-based developer and operator of proprietary technology applications. With a global presence, the company has three main segments: Mobility, Delivery, and Freight. Founded in 2009, Uber is committed to creating opportunity through movement.

5. Super Group (SGHC) Limited (NYSE:SGHC)

Upside potential as of June 11, 2025: 27.07%

Analysts at BTIG Research have reaffirmed the “Buy” rating on Super Group (SGHC) Limited (NYSE:SGHC), while raising the price target to $11 from $9, signaling a surge of about 18% from the current stock price. This price appreciation followed the company’s financial model updates to include a change in the company’s presentation currency and the optimism surrounding Sportsbook operations in the years ahead.

While the company’s revenue guidance didn’t impress investors, the strategy management is taking is what’s exciting. The company is wise enough to leverage its most profitable regions, particularly Africa and Canada, which are the key revenue drivers. Some analysts believe that if Super Group (SGHC) Limited (NYSE:SGHC) is able to manage a revenue growth of 30% to 40%, the profits derived from Africa will almost double.

That’s not it. The giant isn’t hitting a pause on product innovation either. From new betting products to gaming offerings, Super Group (SGHC) Limited (NYSE:SGHC) is not only retaining existing customers but also attracting new ones. What’s truly impressive is that the management knows that the art is in efficiently utilizing the costs, and not in driving down costs. Through this, the execution of strategic partnerships and the building of brand strength become quite easy.

Super Group (SGHC) Limited (NYSE:SGHC) is a Guernsey-based online sports betting and gaming operator. With a presence in Africa, the Middle East, the Asia-Pacific, Europe, North America, and South/Latin America, the company operates through two segments: Betway and Spin.

4. Banco Macro S.A. (NYSE:BMA)

Upside potential as of June 11, 2025: 44%

GAMMA Investing LLC, an institutional asset management expert, raised its stake in Banco Macro S.A. (NYSE:BMA) by 9,810.7% during the first quarter. Adding 76,916 shares to the existing 77,700 shares of the bank’s stock enhanced the ownership to 0.12% worth $5,867,000 at the end of the recent reporting period. This isn’t merely a vote of confidence; it’s a consequence of deep analysis.

In its latest earnings report, Banco Macro S.A. (NYSE:BMA) revealed an interesting strategy for the future. Management’s belief in organic growth, together with the high probability of Argentina’s banks shrinking, means that the company will seize the first valuable acquisition that comes its way.

Market sentiment, too, leans towards optimism. For instance, analysts at Yahoo Finance have set a one-year price target of $110.14, signaling an upside of around 44% from the current price of $76.79. This strongly indicates that Banco Macro S.A. (NYSE:BMA) is poised to grow in the years ahead.

Banco Macro S.A. (NYSE:BMA), incorporated in 1966 and headquartered in Buenos Aires, Argentina, is a financial institution that provides its services to individuals, small- and medium-sized businesses, and corporate clients. The company’s core offerings include retail and corporate banking products and services, personal loans and residential mortgages, transaction services, and corporate lending products.

3. Travere Therapeutics, Inc. (NASDAQ:TVTX)

Upside potential as of June 11, 2025: 136.01%

HC Wainwright & Co., a leading investment bank, has initiated a “Buy” rating for Travere Therapeutics, Inc. (NASDAQ:TVTX), with a price target of $30, signaling an upside of around 100%. This confidence in the company underscores its position in the pharmaceutical sector.

The company has just announced plans to present three new abstracts underscoring the impact of FILSPARI (sparsentan) in rare kidney disease at the International Podocyte Conference, taking place in Hamburg, Germany. The findings of FILSPARI, showcasing advanced reductions in urinary BAFF and sC5b9, along with dips in the proinflammatory and profibrotic biomarkers, signal a step forward in the treatment of IgAN.

With net sales of FILSPARI increasing 182% year-over-year and the successful approval of FILSPARI in Europe and the UK, analysts have little doubt about the company’s potential. Since the major revenue contribution comes from FILSPARI, the rising popularity and increasing adoption among nephrologists mean that Travere Therapeutics, Inc. (NASDAQ:TVTX) can continue to leverage a product that is quite differentiated.

Travere Therapeutics, Inc. (NASDAQ:TVTX) is a biopharmaceutical company incorporated in 2008. This California-based giant recognizes, develops, and commercializes therapies for people suffering from rare kidney and metabolic diseases in the United States.

2. ACCO Brands Corporation (NYSE:ACCO)

Upside potential as of June 11, 2025: 156.5%

ACCO Brands Corporation (NYSE:ACCO) is undergoing major restructuring in line with its long-running restructuring and cost-saving initiative. This $341.926 million market capitalization company has announced several changes to the senior executive leadership team.

When a company starts to refresh its team, the impact on numbers and strategies is loud, and that’s what will happen with ACCO Brands Corporation (NYSE:ACCO). Although it has often performed poorly in the past, the company seems to be going in a new direction. Analysts at Yahoo Finance maintain a one-year price target of $9.67, implying an upside of over 150% from the current levels. Other analysts share similar views while keeping an “Outperform” rating for the stock.

Through these changes, the company aims to streamline its operations, position prominent leaders closer to customers, and unlock additional value from its global sourcing capabilities. As the President and CEO of ACCO Brands Corporation (NYSE:ACCO) stated,

“We are focused on delivering sustained, profitable sales growth, and our leadership team is committed to providing value to our customers and consumers.”

ACCO Brands Corporation (NYSE:ACCO) is an Illinois-based leading company that designs, produces, and commercializes various branded business, consumer, and academic products. Founded in 1893, the giant operates through two main segments: ACCO Brands Americas and ACCO Brands International. The company is well-positioned in the global market from the Middle East and Asia to Europe and Australia.

1. Telomir Pharmaceuticals, Inc. (NASDAQ:TELO)

Upside potential as of June 11, 2025: 688%

On Wednesday, Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) revealed that its leading product, Telomir-1, showcased a marked improvement in the neurological, liver, and kidney symptoms observed in a preclinical animal model of Wilson’s disease.

In a zebrafish model mimicking Wilson’s disease, the drug showed substantial dose-dependent improvements, including a decrease in tremors, a normal swimming behavior, and a 50% reduction in copper accumulation in liver tissue. It also led to better liver and kidney histopathology while restoring key biomarkers. As Dr. Angel, Chief Scientific Advisor at Telomir Pharmaceuticals, Inc. (NASDAQ:TELO), mentioned,

“These recent findings establish Telomir-1 as a potent disease-modifying compound in a clinically relevant model of Wilson’s disease.”

With a market capitalization of $59.079 million, the company is also positioning its drug through IND-enabling studies, with plans to submit its first IND for a rare disease by the year’s end, followed by human trials in the first half of the next year.

Analysts have set a price target of $15.50 for Telomir Pharmaceuticals, Inc. (NASDAQ:TELO), implying an upside of a whopping 688%. These well-structured plans highlight the company’s position to lead the global market in the years ahead.

Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) is a pre-clinical stage biopharmaceutical company that emphasizes the reversal of oxidative stress, cellular protection, and regulatory mechanisms. Incorporated in 2021, this Florida-based company is designing and developing products to address the causes of rare diseases.

READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.

Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.